NEI Research News

Around Halloween time, health experts fear that consumers will harm their eyes with unapproved decorative contact lenses.

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.

Study estimates prevalence of vision disorders among preschool children in three ethnic groups, identifies risk factors

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).

In October 2009, the FDA, the National Eye Institute, and the Department of Defense launched the LASIK Quality of Life Collaboration Project.

More than 72,000 clinical photographs illustrate age-related eye disease progression

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

Los investigadores determinaron que los latinos presentan mayores índices de deterioro visual, ceguera, enfermedad diabética del ojo y cataratas que los blancos no hispanos.

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos.